Abstract
Background Although angiotensin receptor-neprilysin inhibitor (ARNI) therapy has been shown to improve outcomes in heart failure with reduced ejection fraction (HFrEF), its benefits in patients with end-stage renal disease (ESRD) on dialysis remain uncertain. This study investigated the clinical outcomes of ARNI compared to renin-angiotensin system (RAS) blockers in HFrEF patients with concomitant ESRD on dialysis.
Methods Using the Korean National Health Insurance Service database, we identified individuals with HFrEF and ESRD on dialysis who were prescribed either ARNI or RAS blockers between 2017 and 2021. After applying inverse probability of treatment weighting, we compared 2,104 patients on ARNI with 2,191 on RAS blockers. The primary endpoint was a composite of all-cause mortality and any hospitalization over 2 years.
Results Baseline characteristics were balanced between the groups. ARNI use was associated with a significantly lower risk of the primary endpoint (hazard ratio [HR] 0.86, 95% confidence interval [CI] 0.75–0.97) compared to RAS blockers. Additionally, ARNI was associated with a lower risk of all-cause mortality (HR 0.68, 95% CI 0.54–0.86) and any hospitalization (HR 0.86, 95% CI 0.75–0.98). Subgroup analyses demonstrated consistent associations between ARNI use and reduced risk across all subgroups (age, sex, comorbidities, and medications). Good adherence to ARNI was associated with a lower risk of the primary outcome, whereas non-adherence showed no such benefit.
Conclusion In a real-world population with HFrEF and ESRD on dialysis, ARNI use was associated with a lower risk of all-cause mortality and hospitalization compared to RAS blockers, particularly in those with good adherence to therapy.
In this real-world study of patients with heart failure with reduced ejection fraction (HFrEF) and end-stage renal disease (ESRD) on dialysis, the use of angiotensin receptor-neprilysin inhibitor (ARNI) was associated with a significant reduction in the risk of all-cause mortality and any hospitalization compared to renin-angiotensin system (RAS) blockers. These benefits were particularly evident in patients who adhered well to their medication.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by Novartis Pharmaceuticals, by the Bio & Medical Technology Development Program of the National Research Foundation (NRF), funded by the Korean government (MSIT) (No. RS-2024-00440824 and RS-2022-00166313), by the Korea Disease Control and Prevention Agency (2019-ER6303-00, 2019-ER6303-01, 2019-ER6303-02, 2022-ER0908-00, 2022-ER0908-01, and 2022-ER0908-02) and by the Korea National Institute of Health (KNIH) (Project Nos. 2023ER080600 and 2023ER080601). The funding organizations had no role in the study's design, data collection, analysis, interpretation, or manuscript preparation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The local institutional review board reviewed and approved the study protocol (IRB No. CR321358). Participant consent was waived because anonymized data were provided by the NHIS under a strict confidentiality protocol.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The study findings are supported by data from the NHIS, which can be accessed upon review and approval of a study proposal by the NHIS.
